UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors

Talapatra, SK; Tham, CL; Guglielmi, P; Cirilli, R; Chandrasekaran, B; Karpoormath, R; Carradori, S; (2018) Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors. European Journal of Medicinal Chemistry , 156 pp. 641-651. 10.1016/j.ejmech.2018.07.006. Green open access

[thumbnail of Kozielski_Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors_AAM.pdf]
Preview
Text
Kozielski_Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors_AAM.pdf - Accepted Version

Download (1MB) | Preview

Abstract

The thiadiazole scaffold is an important core moiety in a variety of clinical drug candidates targeting a range of diseases. For example, the 2,4,5-substituted 1,3,4-thiadiazole scaffold is present in a lead compound and at least two clinical candidates targeting the human motor protein Eg5, against neoplastic diseases. An inhibitor named K858 has in vivo activity in various mouse xenografts whereas the clinical candidates (S)-ARRY-520 and (R)-Litronesib have entered clinical trials with the former one in phase III clinical trials either alone or in combination with a proteasome inhibitor against relapsed/refractory multiple myeloma. Astonishingly, structural data are lacking for all thiadiazole-containing Eg5 inhibitors. Here we report the structure determination of two crystal forms of the ternary Eg5-ADP-K858 complex, locking the motor in the so-called final inhibitor bound state, thus blocking ADP release, a crucial stage for Eg5 activity. K858 acts at the established allosteric inhibitor-binding pocket formed of helix α2, loop L5 and helix α3. The structure of the complex has far reaching consequences for thiadiazole containing Eg5 inhibitors. For example, we could rationalise the structure-activity relationship in the crucial 5-position of the thiadiazole scaffold and the complex will serve in the future as a basis for strucutre-based drug design.

Type: Article
Title: Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors
Location: France
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ejmech.2018.07.006
Publisher version: https://doi.org/10.1016/j.ejmech.2018.07.006
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: 1,3,4-thiadiazole, K858 enantiomers, Eg5, Antimitotic drugs, Eg5-K858 complex, Rational drug design
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharma and Bio Chemistry
URI: https://discovery.ucl.ac.uk/id/eprint/10056867
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item